bYoRNA
- Biotech or pharma, therapeutic R&D
- CMO, CRO
- Biotech or pharma, animal health
bYoRNA is a French biotechnology company developing a cost-efficient and scalable platform for producing self-amplifying (saRNA) and long mRNA. Our patented technology uses recombinant yeast cells to produce longer, more efficient and less immunogenic RNA at a fraction of the current cost. This is especially relevant for oncological mRNA vaccines and gene therapy.
We have secured 3M€ of grants and pre-seed financing, with two venture capital firms willing to reinvest in our seed round. We have a partnership with TRON, the German mRNA research institute created by the founders of BioNTech. We have improved the productivity of the process 50-fold in two years and we expect to have two animal PoCs and a large pharma partnership within the next 12 months.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}